http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이성환(Sunghwan Lee),김보연(Boyeon Kim),이동영(Dongyoung Yi),장낙원(Nakwon Jang) 대한전기학회 2006 대한전기학회 학술대회 논문집 Vol.2006 No.10
In this paper, we will treat the diagnosis problem to accurately determine fault types. The judgement of fault types is accomplished by observing the cluster newly formed with faults and clustering the input current waveforms to intrinsically show the conditions with the dignet that is a clustering algorithm. The types of input current waveforms are, however, constrained during normal operation, though it considers the load character. In case of faults, new clusters are generated outside the clusters, which appear during normal operation, because the input Current waveforms of the induction motor are generated by the type which is not observed in case of faults. The diagnosis about the types of faults is essential to building a fault tree about the induction motor, and it removes the causes of the faults using a fuzzy logic. We, first, constitute a fault tree, which connects with the parts and the entire system of the induction motor, and investigate fault modes which can be generated from the fault tree and the relationship of the cause and the effect of each part (of the motor). Also, we distinguish the faults of each part by means of inducing the said of fuzzy relation equations encapsulating the relationship of the fault modes and each part.
( Sojung Han ),( Do Young Kim ),( Ho Yeong Lim ),( Jung Hwan Yoon ),( Baek-yeol Ryoo ),( Yujeong Kim ),( Kook-hee Kim ),( Boyeon Kim ),( So Young Yi ),( Dong-sook Kim ),( Doyeon Cho ),( Jina Yu ),( Su 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: The purpose of this study was to investigate the characteristics, treatment patterns including subsequent treatment and outcomes of sorafenib of whole HCC patients in South Korea. Methods: This is a retrospective, single-arm, and observational study. Data sources came from the national health insurance data. Included patients were those who had been diagnosed as HCC and received sorafenib between 1 July 2008 and 31 December 2014. A total of 9,923 patients were recruited in this study. Results: The mean age of 9,923 patients were 59 years with male predominance (84.6%). The mean HCC-prevalent duration was 663 days (22.1 months). The most common etiology of HCC was hepatitis B (66%). Before sorafenib treatment, 6,669 (67.2%) patients received other kinds of therapies for HCC including transarterial chemoembolization (TACE), resection and radiation therapy. During sorafenib therapy, 1,565 (15.8%) received combined treatment with other modalities. After sorafenib therapy, 2,591 (26.1%) patients received rescue therapies, of which TACE was the most common modality applied in 1,498 (15.1%) patients. The mean duration of sorafenib administration in all the patients was 105.7 days. In 7,159 (72.2%) patients, the initial and mean sorafenib dose were the same. There were 7,023 (70.8%) patients whose initial sorafenib dose was 600-800mg. The survival was longest in patients with recommended starting dose of 800mg, followed by dose reduction to 400mg (15.0 months). The second longest survival was demonstrated in patients with starting dose of 800mg, followed by dose reduction to 400-600mg (9.6 months). A total of 3,591 patients underwent rescue therapy after sorafenib, and the median OS was 14.5 months which were longer than 4.6 months in 7,332 patients who received supportive care after sorafenib. The most commonly applied treatment after sorafenib was TACE (30.8%). Conclusions: Real-life data show that the efficacy of sorafenib seems to be similar with that in clinical trials. Appropriate subsequent therapy after sorafenib might prolong the patient survival.